Participation of Accelmed, a leading medical device investor, validates the compelling market potential of the company’s EsophyX technology REDMOND, Wash., May 28, 2019-- EndoGastric Solutions® today announced the closing of its Series I financing at a total of $45 million. Accelmed, a leading growth capital medical device investor, joined the round, which had previously raised $30.5 million. The company intends to use the proceeds from this financing to further accelerate commercialization efforts in support of the growing market demand for its Transoral Incisionless Fundoplication (TIF® 2.0) procedure performed with the EsophyX® device.